Covid-19 roundup: FDA stamps quick OK on Roche's Actemra PhIII; AlloVir expands Baylor pact
→ The FDA has offered a quick OK for Genentech to start a Phase III trial using their rheumatoid arthritis drug Actemra against Covid-19. And the big Roche subsidiary is sending in 10,000 doses for the US stockpile.
Genentech is working with BARDA on the study, which has established primary and secondary endpoints that include “clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,700+ biopharma pros reading Endpoints daily — and it's free.